Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

N Engl J MedAug 28, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)

Daehoon Kim, Young Soo Lee, Jaemin Shim et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial evaluated the efficacy of direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation at intermediate stroke risk in South Korea. Among 1803 participants, DOAC therapy resulted in a significantly lower incidence of primary endpoint events (0.5% vs 1.5%) compared to no anticoagulation at 24 months (P = 0.03).

Key findings

  • Primary endpoint events occurred in 4 patients (0.5%) in the DOAC group versus 13 (1.5%) in the no-anticoagulant group.
  • Stroke incidence was 0.3% in the DOAC group compared to 1.1% in the no-anticoagulant group.
  • Serious adverse events were similar between groups: 8.9% in the DOAC group and 9.3% in the no-anticoagulant group.

Why it matters

The findings support the use of DOAC therapy in patients with atrial fibrillation at intermediate stroke risk, potentially guiding clinical decision-making regarding anticoagulation strategies in this population.

Source

PubMed · PMID 42663303

Published in N Engl J Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.